© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 3-4, 166-173,
February 21, 1996
© 1996 Oxford University Press
Follow-up Prostate Cancer Treatments After Radical Prostatectomy: a Population-Based Study
Center for Evaluative Clinical Sciences, Dartmouth Medical School Hanover, NH
Surveillance Program, Division of Cancer Prevention and Control, National Cancer Institute Bethesda, MD
Department of Surgery, Division of Urology, University of Connecticut Farmington
Medical Practices Evaluation Center, Massachusetts General Hospital Boston
Correspondence to present address: Grace L. Lu-Yao. Ph.D., M.P.H., Office of Research and Demonstrations. Division of Health Information and Outcomes, Health Care Financing Administration, Mail Stop C3-24-07. 7500 Security Blvd., Baltimore, MD 21244-1850.
BACKGROUND: Radical prostatectomy is one of the most commonly used curative procedures for the treatment of localized prostate cancer. The probability that a patient will undergo additional cancer therapy after this procedure is largely unknown.
PURPOSE: The objective was to determine the likelihood of additional cancer therapy after radical prostatectomy.
METHODS: Data for this study were derived from a linked dataset that combined information from the Surveillance, Epidemiology, and End Results Program and Medicare hospital and physician claims. Records were included in this study if patient histories met the following criteria: (a) residing in Connecticut, Washington (Seattle-Puget Sound), or Georgia (Metropolitan Atlanta); (b) having been diagnosed with prostate cancer during the period from January 1, 1985, through December 31, 1991; (c) undergoing radical prostatectomy by December 31, 1992; and (d) having no evidence of other types of cancer. Patients were considered to have had additional cancer therapy if they had had radiation therapy, orchiectomy, and/or androgen-deprivation therapy by injection after radical prostatectomy. The interval between the initial treatment and any follow-up treatment was calculated from the date of radical prostatectomy to the 1st day of the follow-up cancer therapy. All presented probabilities are based on Kaplan—Meier estimates.
RESULTS: The study population consisted of 3494 Medicare patients, 3173 of whom underwent radical prostatectomy within 3 months of prostate cancer diagnosis. Although radical prostatectomy is often reserved for localized cancer, less than 60% (1934) of patients whose records were included in this study had organ-confined disease, according to final surgical pathology. Overall, the 5-year cumulative incidence of having any additional cancer treatment after radical prostatectomy reached 34.9% (95% confidence interval [CI] = 31.5%–38.5%). For patients with pathologically organ-confined cancer, the 5-year cumulative incidence was 24.3% (95% CI = 20.0%–29.3%) overall and ranged from 15.6% (95% CI = 9.7%–24.5%) for well-differentiated cancer (Gleason scores 2–4) to 41.5% (95% CI = 27.9%–58.4%) for poorly differentiated cancer (Gleason scores 8–10). The corresponding figures for pathologically regional cancer were 22.7% (95% CI = 12.0%–40.5%) and 68.1% (95% CI = 58.7%–77.1%).
CONCLUSION: Further treatment of prostate cancer was done in about one third of patients who had had a radical prostatectomy with curative intent and in about one quarter of patients who were found to have organ-confined disease.
IMPLICATIONS: Given the common requirement for follow-up cancer treatments after radical prostatectomy and the uncertainties about the effectiveness of the various follow-up treatment strategies, further investigation of these treatments is warranted. [J Natl Cancer Inst 1996;88:166–73]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. S. Thaxton, R. Elghanian, A. D. Thomas, S. I. Stoeva, J.-S. Lee, N. D. Smith, A. J. Schaeffer, H. Klocker, W. Horninger, G. Bartsch, et al. From the Cover: Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy PNAS, November 3, 2009; 106(44): 18437 - 18442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Hu, X. Gu, S. R. Lipsitz, M. J. Barry, A. V. D'Amico, A. C. Weinberg, and N. L. Keating Comparative Effectiveness of Minimally Invasive vs Open Radical Prostatectomy JAMA, October 14, 2009; 302(14): 1557 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. W. Brawley, D. P. Ankerst, and I. M. Thompson Screening for Prostate Cancer CA Cancer J Clin, July 1, 2009; 59(4): 264 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lucia, A. K. Darke, P. J. Goodman, F. G. La Rosa, H. L. Parnes, L. G. Ford, C. A. Coltman Jr., and I. M. Thompson Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention Cancer Prevention Research, August 1, 2008; 1(3): 167 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Hu, Q. Wang, C. L. Pashos, S. R. Lipsitz, and N. L. Keating Utilization and Outcomes of Minimally Invasive Radical Prostatectomy J. Clin. Oncol., May 10, 2008; 26(14): 2278 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Edwards, M. L. Brown, P. A. Wingo, H. L. Howe, E. Ward, L. A. G. Ries, D. Schrag, P. M. Jamison, A. Jemal, X. C. Wu, et al. Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment J Natl Cancer Inst, October 5, 2005; 97(19): 1407 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Thompson, D. P. Ankerst, C. Chi, M. S. Lucia, P. J. Goodman, J. J. Crowley, H. L. Parnes, and C. A. Coltman Jr Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower JAMA, July 6, 2005; 294(1): 66 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Pisansky External Beam Radiotherapy as Curative Treatment of Prostate Cancer Mayo Clin. Proc., July 1, 2005; 80(7): 883 - 898. [Abstract] [PDF]
|
|
|
|
|
|
N. L. Keating, M. B. Landrum, E. Meara, P. A. Ganz, and E. Guadagnoli Do Increases in the Market Share of Managed Care Influence Quality of Cancer Care in the Fee-For-Service Sector? J Natl Cancer Inst, February 16, 2005; 97(4): 257 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bermejo, A. R. Kristal, S. B. Zeliadt, S. Ramsey, and I. M. Thompson Localized Prostate Cancer: Quality of Life Meets Whitmore's Legacy J Natl Cancer Inst, September 15, 2004; 96(18): 1348 - 1349. [Full Text] [PDF]
|
|
|
|
|
|
B. A. Spencer, M. Steinberg, J. Malin, J. Adams, and M. S. Litwin Quality-of-Care Indicators for Early-Stage Prostate Cancer J. Clin. Oncol., May 15, 2003; 21(10): 1928 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Malin, K. L. Kahn, J. Adams, L. Kwan, M. Laouri, and P. A. Ganz Validity of Cancer Registry Data for Measuring the Quality of Breast Cancer Care J Natl Cancer Inst, June 5, 2002; 94(11): 835 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. U. Shipley, H. D. Thames, H. M. Sandler, G. E. Hanks, A. L. Zietman, C. A. Perez, D. A. Kuban, S. L. Hancock, and C. D. Smith Radiation Therapy for Clinically Localized Prostate Cancer: A Multi-institutional Pooled Analysis JAMA, May 5, 1999; 281(17): 1598 - 1604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Albertsen Urology JAMA, June 18, 1997; 277(23): 1904 - 1905. [PDF]
|
|